Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02141438 · ClinicalTrials.gov registry record

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

A clinical trial of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bayer.

Completed
Registry status
1,472
Enrollment target
20
Study locations

NCT02141438 is a study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by Bayer. The registered enrollment target is 1,472 participants, above the 177-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (732% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02141438, a study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by Bayer.

COMPLETED
Registry status
1,472 participants
Enrollment target
20
Study locations

Study Summary

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Radium-223 dichloride (Xofigo, BAY88-8223)

Study Locations (20)

Florida

  • - Boca Raton
  • - Fort Myers
  • - Jacksonville
  • - Lakewood Rch
  • - Plantation

California

  • - Daly City
  • - Long Beach
  • - Sacramento
  • - San Diego

Georgia

  • - Atlanta
  • - Decatur

Illinois

  • - Evanston
  • - Warrenville

Alaska

  • - Anchorage

Arizona

  • - Scottsdale

Colorado

  • - Colorado Springs

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 1,472 participants
Start Date 2014-08-20
Est. Completion 2024-10-24

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02141438

The ClinicalTrials.gov registry entry for NCT02141438 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,472 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (732% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.

NCT02141438 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02141438 about?

NCT02141438 is a clinical study titled "Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer". Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

What is the current status of trial NCT02141438?

This trial is currently completed. The enrollment target is 1,472 participants. The study started on 2014-08-20. Estimated completion is 2024-10-24.

What conditions does trial NCT02141438 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT02141438?

The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).

Who is sponsoring clinical trial NCT02141438?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02141438 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.